Amylyx Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
AMLX
CUSIP
03237H101
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 03237H101 since 12/18/2024, largest first.

Filer % of Class Filed
FMR LLC 13G/A
15.0% 2/5/2026
Event 12/31/2025
Perceptive Advisors LLC 13G/A
8.2% 11/16/2026
Event 9/30/2026
BlackRock, Inc. 13G/A 7.1% 1/21/2026
Event 12/31/2025
TCG Crossover GP II, LLC 13G/A
5.7% 2/17/2026
Event 12/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Point72 Asset Management, L.P. 13G/A
2.6% 11/14/2025
Event 9/30/2025
Panacea Innovation Ltd 13G/A
2.6% 2/14/2025
Event 12/31/2024
Adage Capital Management, L.P. 13G/A
2.5% 2/12/2026
Event 12/31/2025
Commodore Capital LP 13G/A
1.6% 11/16/2026
Event 9/30/2026
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 231 132 M $3.85B
2026 Q2 207 115 M $2.07B
2026 Q1 173 114 M $1.59B
2025 Q4 182 112 M $1.36B
2025 Q3 173 110 M $1.49B
2025 Q2 132 81.7 M $524M
2025 Q1 137 73.9 M $262M
2024 Q4 126 49.8 M $188M
2024 Q3 116 43.5 M $141M
2024 Q2 124 43.6 M $82.9M
2024 Q1 153 49.5 M $141M
2023 Q4 185 60.3 M $887M
2023 Q3 176 58.9 M $1.08B
2023 Q2 159 54.5 M $1.18B
2023 Q1 155 51.4 M $1.51B
2022 Q4 137 48.6 M $1.79B
2022 Q3 103 37.3 M $1.05B
2022 Q2 83 26.6 M $513M
2022 Q1 73 23.4 M $300M